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ABSTRACT
Background and Aims Electronic cigarettes (e-cigarettes) are rapidly increasing in popularity. Two randomized
controlled trials have suggested that e-cigarettes can aid smoking cessation, but there are many factors that could
influence their real-world effectiveness. This study aimed to assess, using an established methodology, the effectiveness
of e-cigarettes when used to aid smoking cessation compared with nicotine replacement therapy (NRT) bought over-
the-counter and with unaided quitting in the general population. Design and Setting A large cross-sectional survey
of a representative sample of the English population. Participants The study included 5863 adults who had smoked
within the previous 12 months and made at least one quit attempt during that period with either an e-cigarette only
(n = 464), NRT bought over-the-counter only (n = 1922) or no aid in their most recent quit attempt (n = 3477).
Measurements The primary outcome was self-reported abstinence up to the time of the survey, adjusted for key
potential confounders including nicotine dependence. Findings E-cigarette users were more likely to report absti-
nence than either those who used NRT bought over-the-counter [odds ratio (OR) = 2.23, 95% confidence interval
(CI) = 1.70–2.93, 20.0 versus 10.1%] or no aid (OR = 1.38, 95% CI = 1.08–1.76, 20.0 versus 15.4%). The adjusted
odds of non-smoking in users of e-cigarettes were 1.63 (95% CI = 1.17–2.27) times higher compared with users of
NRT bought over-the-counter and 1.61 (95% CI = 1.19–2.18) times higher compared with those using no aid.
Conclusions Among smokers who have attempted to stop without professional support, those who use e-cigarettes
are more likely to report continued abstinence than those who used a licensed NRT product bought over-the-counter
or no aid to cessation. This difference persists after adjusting for a range of smoker characteristics such as nicotine
dependence.
Keywords Cessation, cross-sectional population survey, e-cigarettes, electronic cigarettes, nicotine replacement
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INTRODUCTION
Smoking is one of the leading risk factors for premature
death and disability and is estimated to kill 6 million
people world-wide each year [1]. The mortality and mor-
bidity associated with cigarette smoking arises primarily
from the inhalation of toxins other than nicotine
contained within the smoke. Electronic cigarettes
(e-cigarettes) provide nicotine via a vapour that is drawn
into the mouth, upper airways and possibly lungs [2,3].
These devices use a battery-powered heating element
activated by suction or manually to heat a nicotine solu-
tion and transform it into vapour. By providing a vapour
containing nicotine without tobacco combustion,
e-cigarettes appear able to reduce craving and with-
drawal associated with abstinence in smokers [2,4,5],
while toxicity testing suggests that they are much safer to
the user than ordinary cigarettes [3].
E-cigarettes are increasing rapidly in popularity:
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States appears to have increased from approximately 2%
in 2010 to more than 30% in 2012, and the rate of
increase appears to be similar in the United Kingdom
[6–9]. Although there are concerns about their wider
public health impact relating to the renormalization of
smoking and promotion of smoking in young people, cru-
cially two randomized controlled trials have suggested
that e-cigarettes may aid smoking cessation [10,11].
However, there are many factors that influence real-
world effectiveness, including the brand of e-cigarette,
the way they are used and who chooses to use them [12].
Therefore, it is a challenge to establish probable contribu-
tion to public health through randomized efficacy trials
alone. Moreover, this kind of evidence will take many
years to emerge, and in the meantime the products are
developing rapidly and countries require evidence on
effectiveness to inform decisions on how to regulate them
[13–19]. As a result, there is an urgent need to be able to
make an informed judgement on the real-world effective-
ness of currently popular brands as chosen by the mil-
lions of smokers across the world who are using them in
an attempt to stop smoking [6–9].
Several studies have attempted to examine the rela-
tionship between the use of e-cigarettes and smoking
status in the real world by surveying regular e-cigarette
users [20–27]. These studies—including one using a lon-
gitudinal design [27]—have found that users consistently
report that e-cigarettes helped them to quit or reduce
their smoking. However, because the samples were self-
selected, the results have to be interpreted with caution.
In more general samples the evidence is less positive. One
national study of callers to a quitline, which assessed the
cross-sectional association of e-cigarette use and current
smoking status at a routine follow-up evaluation of the
quitline service, found that e-cigarette users compared
with never users were less likely to be abstinent [28]. In a
longitudinal study of a general population sample,
e-cigarette users at baseline were no more likely to have
quit permanently at a 12-month follow-up despite having
reduced their cigarette consumption [29]. However,
neither of these studies adjusted for important potential
confounding variables and both evaluated the associa-
tion between quitting and the use of e-cigarettes for any
purpose, not specifically as an aid to quitting. It is crucial
to distinguish between the issue of whether use of
e-cigarettes in a quit attempt improves the chances of
success of that attempt from the issue of whether the use
of e-cigarettes, for whatever purpose, such as aiding
smoking reduction or recreation, promotes or suppresses
attempts to stop. In determining the overall effect on
public health both considerations are important, but they
require different methodologies to address them.
An ongoing national surveillance programme (the
Smoking Toolkit Study) has been tracking the use of
e-cigarettes as a reported aid to cessation among the
general population in England since July 2009 [30]. This
programme has established a method of assessing real-
world effectiveness of aids to cessation by comparing the
success rates of smokers trying to quit with different
methods and adjusting statistically for a wide range of
factors that could bias the results, such as nicotine
dependence [31]. The method has been able to detect
effects of behavioural support and prescription medica-
tions to aid cessation and found a higher rate of success
when using varenicline than prescription nicotine
replacement therapy (NRT) [32,33], supporting findings
from randomized controlled trials and clinical observa-
tion studies [34–37]. This method cannot achieve the
same level of internal validity as a randomized controlled
trial, but clearly has greater external validity, so both are
important in determining the potential public health con-
tribution of devices hypothesized to aid cessation, such as
e-cigarettes.
Given that smokers already have access to licensed
NRT products, it is important to know whether
e-cigarettes are more effective in aiding quitting. This
comparison is particularly important for two reasons.
First, buying a licensed NRT product from a shop, with no
professional support, is the most common way of using it
in England, and secondly, previous research has found
that this usage was not associated with greater success
rates than quitting unaided in the real-world [33]. It
is therefore important to know whether e-cigarettes
can increase abstinence compared to NRT bought
over-the-counter.
The current study addressed the question of how
effective e-cigarettes are compared with NRT bought
over-the-counter and unaided quitting in the general
population of smokers who are attempting to stop.
METHODS
Study design
The design was cross-sectional household surveys of rep-
resentative samples of the population of adults in
England conducted monthly between July 2009 and Feb-
ruary 2014. To examine the comparative real-world
effectiveness of e-cigarettes, the study compared the self-
reported abstinence rates of smokers in the general popu-
lation trying to stop who used e-cigarettes only (i.e.
without also using face-to-face behavioural support or
any medically licensed pharmacological cessation aid)
with those who used NRT bought over-the-counter only
or who made an unaided attempt, while adjusting for a
wide range of key potential confounders. The surveys
are part of the ongoing Smoking Toolkit Study, which
is designed to provide information about smoking
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prevalence and behaviour in England [30]. Eachmonth a
new sample of approximately 1800 adults aged ≥16
years are selected using a form of random location sam-
pling, and complete a face-to-face computer-assisted
survey with a trained interviewer. The full methods have
been described in detail and shown to result in a sample
that is nationally representative in its socio-demographic
composition and proportion of smokers [30]. Approval
was granted by the ethics committee of University College
London, UK.
Study population
For the current study, we used aggregated data from
respondents to the survey in the period from July 2009
(the first wave to track use of e-cigarettes to aid cessation)
to February 2014 (the latest wave of the survey for which
data were available), who smoked either cigarettes
(including hand-rolled) or any other tobacco product
(e.g. pipe or cigar) daily or occasionally at the time of the
survey or during the preceding 12 months. We included
those who had made at least one quit attempt in the pre-
ceding 12 months, assessed by asking: ‘How many
serious attempts to stop smoking have you made in the
last 12 months? By serious attempt I mean you decided
that you would try to make sure you never smoked again.
Please include any attempt that you are currently
making and please include any successful attempt made
within the last year’. We included respondents who used
either e-cigarettes or NRT bought over-the-counter
during their most recent quit attempt, and an unaided
group defined as those who had not used any of the fol-
lowing: e-cigarettes; NRT bought over-the-counter; a pre-
scription stop-smoking medication; or face-to-face
behavioural support. We excluded those who used either
e-cigarettes or NRT bought over-the-counter in combina-
tion with one another, a prescription stop-smoking medi-
cation or face-to-face behavioural support.
Measurement of effect: quitting method
The use of different quitting methods were assessed for
the most recent attempt by asking: ‘Which, if any, of the
following did you try to help you stop smoking during the
most recent serious quit attempt?’ and included: (i)
e-cigarettes; (ii) NRT bought over-the-counter; (iii) no aid
(i.e. had not used any of e-cigarettes, NRT bought over-
the-counter, a prescription stop-smoking medication or
face-to-face behavioural support).
Measurement of outcome: self-reported non-smoking
Our primary outcome was self-reported non-smoking up
to the time of the survey. Respondents were asked: ‘How
long did your most recent serious quit attempt last before
you went back to smoking?’. Those responding ‘I am still
not smoking’ were defined as non-smokers. Previous
research has shown that self-reported abstinence in
surveys of this kind is not subject to the kind of biases
observed in clinical trials where there is social pressure to
claim abstinence [38].
Measurement of potential confounders
We measured variables potentially associated with the
different quitting methods and that may also have an
effect on the outcome. These potential confounders were
chosen a priori. The most important factor was nicotine
dependence, for which we used two questions. First, time
spent with urges to smoke was assessed by asking all
respondents: ‘How much of the time have you felt the
urge to smoke in the past 24 hours? Not at all (coded 0),
a little of the time (i), some of the time (ii), a lot of the time
(iii), almost all of the time (iv), all of the time (v)’. Sec-
ondly, strength of urges to smoke was measured by
asking: ‘In general, how strong have the urges to smoke
been? Slight (i), moderate (ii), strong (iii), very strong (iv),
extremely strong (v)’. This question was coded ‘0’ for
smokers who responded ‘not at all’ to the previous ques-
tion. In this population these two ratings have been found
to be a better measure of dependence (i.e. more closely
associated with relapse following a quit attempt)
than other measures [32,33,39]. The demographic char-
acteristics assessed were age, sex and social grade
(dichotomized into two categories: ABC1, which includes
managerial, professional and intermediate occupations;
and C2DE, which includes small employers and own-
account workers, lower supervisory and technical occu-
pations, and semi-routine and routine occupations, never
workers and long-term unemployed). We also assessed
the number of quit attempts in the last year prior to the
most recent attempt, time since the most recent quit
attempt was initiated (either more or less than 6 months
ago), whether smokers had tried to quit abruptly or
gradually and the year of the survey.
Analysis
Bivariate associations between the use of different quit-
ting methods and potentially confounding socio-
demographic and smoking history variables were
assessed with χ2 tests and one-way analyses of variance
(ANOVA)s for categorical and continuous variables,
respectively. Significant omnibus results were investi-
gated further by post-hoc Sidak-adjusted χ2 tests and
t-tests.
Our measure of dependence (strength of urges to
smoke) assumed that the score relative to other smokers
would remain the same from pre- to post-quitting
[32,33]. If a method of quitting reduced the strength of
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urges to smoke more than another method, this would
tend to underestimate the effectiveness of that interven-
tion because the smokers using this method would
appear to be less dependent. To test for this bias, we used
an analysis of covariance (ANCOVA) to examine whether
the difference in strength of urges to smoke in smokers
versus non-smokers depended upon the method of quit-
ting, adjusting for the time since the quit attempt started.
In the analysis of the associations between quitting
method and abstinence, we used a logistic regression
model in which we regressed the outcome measure (self-
reported non-smoking compared with smoking) on the
effect measure (use of e-cigarettes compared with either
NRT bought over-the-counter or no aid). The primary
analysis was an adjusted model that included the poten-
tial confounders listed above and two interaction terms:
(i) between time since last quit attempt and time spent
with urges, and (ii) between time since last quit attempt
and strength of urges to smoke. These interaction terms
were used to reflect the fact that urges to smoke following
a quit attempt are influenced by whether an individual is
currently abstinent and the duration of abstinence
[32,33]. In addition to themodel from the primary analy-
sis (‘fully adjusted model’; model 4), we constructed a
simple model including only the effect measure (‘unad-
justed model’; model 1), a model that included the effect
measure, year of the survey and all potential confounders
except for the twomeasures of tobacco dependence, and a
model that included all variables from the previousmodel
and the two measures of tobacco dependence but
without their interaction terms (‘partially adjusted
models’; models 2 and 3, respectively) to assess the extent
of confounding by dependence. As post-hoc sensitivity
analyses, the models were re-examined using different
potential confounders from the ones specified a priori and
reported in previous publications using the same meth-
odology [32,33]. First, the time since the initiation of the
quit attempt was included using the following six catego-
ries: ‘in the last week’; ‘more than a week and up to a
month’; ‘more than 1 month and up to 2 months’; ‘more
than 2 months and up to 3 months’; ‘more than 3
months and up to 6 months’; and ‘more than 6 months
and up to a year’. Secondly, an additional index of
dependence—the heaviness of smoking index (HSI)
[40]—was included. The HSI was assessed by asking
current smokers to estimate current cigarettes per day
and time to first cigarette (the two items comprising HSI)
and by asking non-smokers to recall these behaviours
prior to their quit attempt. Finally, in post-hoc subgroup
analyses all models were repeated (i) among those report-
ing smoking one or more than one cigarette per day
(CPD) to determine whether inclusion of very light
smokers might have had an influence on the results; (ii)
among those completing the survey between 2012–14
once e-cigarette usage had become prevalent; and (iii) in
the two subsamples of respondents who had started their
most recent quit attempt less or more than 6months ago,
in order to assess the interplay between long-term effec-
tiveness and the occurrence of differential recall bias. All
analyses were performed with complete cases.
RESULTS
A total of 6134 respondents reported a most recent quit
attempt in the last 12 months that was either unaided
(n = 3477) or supported by NRT bought over-the-counter
(n = 2095), e-cigarettes (n = 489) or both (n = 73). Those
using both were excluded as were those using a prescrip-
tion stop-smokingmedication or face-to-face behavioural
support in combinationwith either NRT bought over-the-
counter (n = 173) or e-cigarettes (n = 25). Thus, the
study population consisted of 5863 smokers who had
made an attempt to quit in the previous year, of whom
7.9% (464) had used e-cigarettes, 32.8% (1922) had
used NRT bought over-the-counter and 59.3% (3477)
had used no aid to cessation. Quitting method did not
differ by sex or the number of quit attempts in the past
year but was associated with age, social grade, time since
the quit attempt started, CPD, smoking less than one CPD,
the measures of dependence (time with and strength of
urges and HSI) and whether the attempt had begun
abruptly (see Table 1). The post-hoc comparisons showed
that those who used either e-cigarettes or no aid were
younger than those usingNRT over-the-counter, and that
those who used NRT over-the-counter or no aid were
more likely to hold a lower social grade than those using
e-cigarettes. As would be expected, given the recent
advent of e-cigarettes, the quit attempts of e-cigarette
users were less likely to have begun more than 6 months
previously than those using NRT over-the-counter or no
aid. Those using NRT bought over-the-counter smoked
more cigarettes and scored higher than either of the
other two groups on all measures of dependence.
E-cigarette users smoked more cigarettes, and were more
dependent by the strength of urges measure and HSI
than those using no aid. Finally, those using no aid were
more likely to have smoked less than one CPD and stopped
abruptly than the other two groups.
Strengths of urges to smoke were higher in smokers
than in non-smokers (see Table 2). However, the mean
differences in strength of urges between smokers and
non-smokers were similar across method of quitting: the
interaction between smoking status (smokers versus non-
smokers) and method of quitting in an ANCOVA of the
strength of urges adjusted for the time since quit attempt
started was not significant (F(2, 5856) = 1.50, P = 0.22).
Non-smokingwas reported among 20.0% (93 of 464)
of those using e-cigarettes, 10.1% (194 of 1922) using
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NRTover-the-counter and 15.4% (535 of 3477) using no
aid. The unadjusted analyses indicated that e-cigarette
users were more likely to be abstinent than either those
using NRT bought over-the-counter [odds ratio
(OR) = 2.23, 95% confidence interval (CI) = 1.70–2.93)
or those who used no aid (OR = 1.38, 95% CI = 1.08–
1.76; see model 1, Table 3). The primary analyses
revealed that the fully adjusted odds of non-smoking in
users of e-cigarettes were 1.63 (95% CI = 1.17–2.27)
times higher compared with users of NRT bought over-
the-counter and 1.61 (95%CI = 1.19–2.18) times higher
compared with those using no aid (see model 4, Table 3).
The relative magnitudes of the ORs from the fully
adjusted model with the other three unadjusted and par-
tially adjustedmodels illustrate the confounding effects of
dependence (see Table 3).
In post-hoc sensitivity analyses, the associations
between quitting method and non-smoking were
re-examined using models including different potential
confounders. In a model including the more fine-grained
assessment of time since the initiation of the quit attempt
than the measure presented in Table 1, the adjusted odds
of non-smoking in users of e-cigarettes were 1.58 (95%
CI = 1.13–2.21) times higher compared with users of
NRT bought over-the-counter and 1.55 (95% CI = 1.14–
2.11) times higher compared with those using no aid. In
another model that included another measure of
dependence (HSI; missing data 3%, n = 172), the
adjusted odds of non-smoking in users of e-cigarettes
were 1.63 (95% CI = 1.15–2.32) times higher compared
with users of NRT bought over-the-counter and 1.43
(95% CI = 1.03–1.98) times higher compared with those
using no aid.
In post-hoc subgroup analyses, very light smokers
were shown to have little influence on the pattern of
results: in repeated analyses among those 5595 smokers
reporting smoking one or more than one CPD the
adjusted odds of non-smoking in users of e-cigarettes
were higher compared with users of NRT bought over-
the-counter (OR = 1.59, 95% CI = 1.13–2.26) and com-
pared with those using no aid (OR = 1.63, 95%
CI = 1.18–2.24). Similarly, the exclusion of respondents






(n = 3477) P
Mean (SD) age 39.0 (15.6)a 41.2 (15.3)ab 37.5 (16.2)b ***
% (n) Female 47.2 (219) 51.1 (982) 48.9 (1699) NS
% Social grade C2DE 59.3 (275)cd 65.9 (1266)c 65.5 (2277)d *
Mean (SD) cigarettes per day¶ 12.6 (8.0)ef 13.8 (8.5)eg 10.9 (8.1)fg ***
% (n) < 1 cigarettes per day¶ 0.7 (3)h 0.8 (15)i 2.8 (94)hi ***
% (n) Time since quit attempt started >26 weeks 23.7 (110)jk 36.4 (700)j 36.5 (1269)k ***
Mean (SD) quit attempts in the past year 1.6 (0.9) 1.6 (0.9) 1.5 (0.9) NS
Mean (SD) time spent with urges to smoke (0–5) 1.9 (1.3)l 2.2 (1.3)lm 1.8 (1.3)m ***
Mean (SD) strength of urges to smoke (0–5) 2.0 (1.2)no 2.2 (1.1)np 1.8 (1.1)op ***
Mean (SD) heaviness of smoking index† 2.0 (1.5)qr 2.3 (1.5)qs 1.6 (1.5)rs ***
% (n) Abrupt attempt (no gradual cutting down first) 50.4 (234)t 52.5 (1010)u 59.0 (2051)tu ***
Different pairs of superscript letters indicate a significant difference (P < 0.05) between two groups after Sidak adjustment for multiple comparisons.
*P < 0.05; ***P < 0.001; NS = not statistically significant (P ≥ 0.05). §A subgroup of those using nicotine replacement therapy (NRT) over-the-counter
provided information about the form of NRT (n = 975): 60.0% (585) used a patch, 21.0% (205) gum, 14.9% (145) an inhalator, 6.2% (60) lozenges,
1.2% (12) microtabs and 1.0% (10) nasal spray. NB: response options were not mutually exclusive and 11.1% (108) reported usingmore than one form.
¶Data were missing for 156 respondents (e-cigarettes: 22; NRT over-the-counter: 34; no aid: 100). †Data were missing for 172 respondents (e-cigarettes:
23; NRT over-the-counter: 36; no aid: 113). SD = standard deviation.
Table 2 Differences between smokers and non-smokers in strength of urges to smoke by method of quitting.
Method of quitting n
Mean (SD) strength of urges
to smoke in smokers n
Mean (SD) strength of urges
to smoke in non-smokers
Mean difference (95% CI) in
strength of urges to smoke
E-cigarettes 371 2.3 (1.1) 93 0.8 (1.1) 1.4 (1.2–1.7)
NRT over-the-counter 1728 2.3 (1.0) 194 1.2 (1.3) 1.2 (1.0–1.3)
No aid 2942 2.0 (1.0) 535 0.7 (1.1) 1.3 (1.2–1.4)
NB: the mean differences are calculated from exact rather than the rounded figures presented in columns 3 and 5 of this table. The mean difference in
strength of urges to smoke was not different across the methods of quitting (F(2, 5856) = 1.50, P = 0.22 for the interaction term between smoking status
and method of quitting adjusted for the time since the quit attempt started). SD = standard deviation; CI = confidence interval; NRT = nicotine replace-
ment therapy.
Real-world effectiveness of e-cigarettes 1535
© 2014 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction, 109, 1531–1540
during a time when e-cigarette usage was relatively rare
(2009–11) had little effect on the results: among those
2306 smokers responding between 2012–14 the
adjusted odds of non-smoking in users of e-cigarettes
were higher compared with users of NRT bought over-
the-counter (OR = 1.59, 95% CI = 1.05–2.42) and those
using no aid (OR = 1.46, 95% CI = 1.04–2.05). In a final
subgroup analysis the models were re-examined among
those who started their quit attempt more or less than
6 months ago: there was only evidence among those
who began their attempts less than 6 months ago of
higher odds of non-smoking in users of e-cigarettes com-
pared with users of NRT bought over-the-counter or
those using no aid in the fully adjusted models (see
Table 3).
DISCUSSION
Respondents who reported having used an e-cigarette in
their most recent quit attempt were more likely to report
still not smoking than those who used NRT bought over-
the-counter or nothing. This difference remained after
adjusting for time since the quit attempt started, year of
the survey, age, gender, social grade, abrupt versus
gradual quitting, prior quit attempts in the same year and
a measure of nicotine dependence.
The unadjusted results have value in that they dem-
onstrate self-reported abstinence is associated with quit-
ting method among those who use these methods to aid
cessation in real-world conditions. However, this was not
a randomized controlled trial and there were differences
in the characteristics of those using different methods.
For example, more dependent smokers tended to be more
likely to use treatment, and smokers from lower social
grades were less likely to use e-cigarettes. Although the
adjustments go beyond what is typically undertaken in
these types of real-world studies [28,29,41–44], it was
not possible to assess all factors that may have been asso-
ciated with the self-selection of treatment and we cannot
rule out the possibility that an unmeasured confounding
factor is responsible for the finding. For example, motiva-
tion to quit is likely to have been associated positivelywith
the use of treatment. However, previous population
studies have found that the strength of this motivation is
not associated with success of quit attempts once started,
so it is unlikely to explain our findings [45]. There are
other variables which are typically related to abstinence
that may also be related to the selection of treatment; for
example, those using e-cigarettes may have been less
likely to share their house with other smokers, had better
mental health or greater social capital of a kind not
measured by social grade. These possibilities mean the
associations reported here must be interpreted with
caution. Nevertheless, the data provide some evidence in
forming a judgement as to whether the advent of
e-cigarettes in the UK market is likely to be having a
Table 3 Associations between quitting method and abstinence.
(1) e-Cigarettes
(2) NRT
over-the-counter (3) No aid
(1) versus (2) (1) versus (3)
Model 1: OR (95% CI) Model 1: OR (95% CI)
Model 2: OR (95% CI) Model 2: OR (95% CI)
Model 3: OR (95% CI) Model 3: OR (95% CI)
Model 4: OR (95% CI) Model 4: OR (95% CI)
Full sample (n = 5863)
% (n) Self-reported
non-smoking
20.0 (93/464) 10.1 (194/1922) 15.4 (535/3477) 2.23 (1.70–2.93)*** 1.38 (1.08–1.76)*
1.88 (1.40–2.52)*** 1.21 (0.92–1.58)
1.63 (1.17–2.28)** 1.62 (1.19–2.19)**
1.63 (1.17–2.27)** 1.61 (1.19–2.18)**
Subsample: quit attempt started ≤26 weeks (n = 3784)
% (n) Self-reported
non-smoking
20.3 (72/354) 11.0 (135/1222) 14.6 (323/2208) 2.06 (1.50–2.82)*** 1.49 (1.12–1.98)**
1.80 (1.27–2.55)*** 1.39 (1.01–1.90)*
1.56 (1.06–2.29)* 1.88 (1.32–2.68)***
– –
Subsample: quit attempt started >26 weeks (n = 2079)
% (n) Self-reported
non-smoking
19.1 (21/110) 8.4 (59/700) 16.7 (212/1269) 2.56 (1.49–4.42)*** 1.18 (0.72–1.94)
1.98 (1.11–3.53)** 0.91 (0.54–1.55)
1.64 (0.83–3.24) 1.10 (0.59–2.06)
– –
Model 1 = unadjusted; model 2 = adjusted for age, sex, social grade, time since quit attempt started, quit attempts in the past year, abrupt versus gradual
quitting and year of the survey; model 3 = adjusted for the variables from model 2 and time spent with urges to smoke and strength of urges to smoke;
model 4 = adjusted for the variables from model 3 and the interaction terms time since last quit attempt started × time spent with urges and time since
last quit attempt started × strength of urges to smoke. NB: for the two subsample analyses, model 4 is redundant, as there is no variation in the time since
quit attempt. *P < 0.05; **P < 0.01; ***P < 0.001. OR = odds ratio; CI = confidence interval; NRT = nicotine replacement therapy.
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positive or negative impact on public health, in away that
a randomized controlled trial is unable to do.
The finding that smokers who had used an e-cigarette
in their most recent quit attempt were more likely to
report abstinence than those who used NRT bought
over-the-counter, and that the latter did not appear to
give better results than not using any aid [33], contrib-
utes to the debate about how far medicine regulation can
go in ensuring that products used for smoking cessation
are or continue to be effective in the real world [14–17].
Randomized controlled trials are clearly important in
identifying potential efficacy, but real-world effectiveness
will depend upon a number of other contextual
variables. The current study, together with previous
randomized trials, suggests that e-cigarettes may prove
to be both an efficacious and effective aid to smoking ces-
sation [10,11]. In so far that this is true, e-cigarettes may
substantially improve public health because of their
widespread appeal [6–9] and the huge health gains asso-
ciated with stopping smoking [46]. This has to be offset
against any detrimental effects that may emerge, as the
long-term effects on health have not yet been estab-
lished. However, the existing evidence suggests the asso-
ciated harm may be minimal: the products contain low
levels of carcinogens and toxicants [3] and no serious
adverse event has yet been reported in any of the numer-
ous experimental studies. Regardless, the harm will
certainly be less than smoking, and thus of greater
importance is the possible long-term effect of e-cigarettes
on cigarette smoking prevalence beyond helping some
smokers to quit. For example, it has been suggested that
e-cigarettes might re-normalize smoking, promote
experimentation among young people who otherwise
may not have tried smoking or lead to dual use together
with traditional cigarettes, and thereby deter some
smokers from stopping [47]. The current data do not
address these issues. However, the rise in e-cigarette
prevalence in England since 2010 has coincided with
continued reduction in smoking prevalence [48].
If e-cigarette use is proving more effective than NRT
bought over-the-counter, a number of factors may con-
tribute to this [49]. A greater similarity between using
e-cigarettes and smoking ordinary cigarettes in terms of
the sensory experience could be one factor. Greater
novelty is another. It is also possible that users of
e-cigarettes use their products more frequently or for a
longer period than those using NRT without professional
support. These are all issues that need to be examined in
future research.
This study was not designed to assess the comparative
effectiveness of e-cigarettes and NRT or other medica-
tions obtained on prescription or behavioural support.
The evidence still favours the combination of behavioural
support and prescription medication as providing the
greatest chance of success [33,34,37], which is currently
offered free at the point of access by the NHS stop
smoking services in the United Kingdom.
A major strength of the current study is the use of a
large, representative sample of the English population.
Additionally, the study benefits from having begun to
track the use of e-cigarettes as an aid to cessation at a
time when e-cigarettes were only an emerging research
issue. The importance of adjusting for nicotine depend-
ence in real-world studies of smoking cessation is illus-
trated by the difference in the ORs between the models
with and without this adjustment. The optimal method
of adjusting for dependence would be to assess this in all
participants prior to their quit attempt. However, in a
wholly cross-sectional study, we believe the particular
method used to adjust for dependence, established in
two previous studies, is valid [32,33]. One of the most
commonly used alternative measures of dependence—
HIS—relies upon the number of cigarettes smoked and
time to first cigarette of the day [40]. When smokers
relapse they tend to do so with reduced consumption,
which can lead to a false estimation of prior dependence
in cross-sectional studies. This potential confound was
avoided in the primary analysis by using a validated
measure involving ratings of current urges to smoke
and statistical adjustment of the urges for the time since
the quit attempt was initiated [39]. The value of
strength of urges as a measure of dependence in cross-
sectional research would be limited if different methods
of stopping were linked differentially to lower or higher
levels of urges in abstinent compared with relapsed
smokers. For example, a method of stopping that led to a
relatively higher reduction in urges could underestimate
the effectiveness of that method by making it seem that
those using it were less dependent. However, we have
not previously found evidence in this population data set
that urges to smoke in smokers versus quitters differs as
a function of method [33], and it was true again in this
study. Regardless, the pattern of results remained the
same in both a sensitivity analysis that also included
HSI and in a subgroup analysis that excluded very light
smokers. It is unlikely, therefore, that differential
dependence between the users of different treatments
has led to a substantial over- or underestimation of the
relative effectiveness of e-cigarettes in the current study.
Nevertheless, future studies may be able to draw
stronger inferences by including a broader array of
dependence measures or assessing dependence prior to a
quit attempt.
The study had several limitations. First, abstinence
was not verified biochemically. In randomized trials, this
would represent a serious limitation because smokers
receiving an active treatment often feel social pressure to
report abstinence. However, in population surveys the
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social pressure and the related rate of misreporting is low
and it is generally considered acceptable to rely upon self-
reported data [38]. A related issue is the assessment of
abstinence by asking respondents whether theywere ‘still
not smoking’. This definition classified as abstinent those
who had one or more lapses but resumed not smoking.
This limitation would be serious if the rate of lapsing was
associated with method of quitting, and should be
assessed in future studies. By contrast, advantages of this
measure were the assessment of prolonged abstinence, as
advocated in the Russell Standard, and a clear relation-
ship to the quit attempt in question. An alternative
approach, with a view to survival analysis, may have
been to assess the length of abstinence since quit date
among all respondents, including thosewho had relapsed
by the time of the survey. However, this assessment would
have added noise and potential bias with smokers
needing to recall the time of relapse and having different
interpretations of their return to smoking (i.e. first lapse,
daily but reduced smoking, or smoking at pre-quit level).
The strength of our approach is that smokers only needed
to know whether they were currently still not smoking.
Secondly, there was a reliance upon recall data. The
assessment of the most recent quit attempt involved
recall of the previous 12months and introduced scope for
bias.The bias associatedwith recall of failed quit attempts
would be expected to reduce the apparent effectiveness of
reported aids to cessation because quit attempts using
such aids would be more salient than those that were
unaided [31]. Therefore, recall bias should militate
against finding a benefit of e-cigarettes compared with no
aid to cessation. Consistent with this explanation, the
effect size for e-cigarettes compared with no aid appeared
lower in smokers who started their quit attempt more
than 6months ago than in smokerswho started their quit
attempt less than 6 months ago. Although the power to
detect the associations in these subgroups was limited,
the explanation that the lack of effect in the more distant
attempts was related to differential recall bias is also sup-
ported by the absolute rate of non-smoking being higher
in thosemaking unaided attemptsmore than 6 compared
with less than 6 months ago. Alternatively, the finding
may reflect a reduced long-term effectiveness of
e-cigarettes. Future longitudinal studies of e-cigarettes as
aids to cessation in the general population may differen-
tiate these explanations and would represent a valuable
improvement upon the current study.
Thirdly, NRT over-the-counter and e-cigarettes both
represent heterogeneous categories. In particular, there is
considerable variability in nicotine vaporization between
different types of e-cigarette [50,51]. Similarly, the simple
definition of using one or the other aid to support an
attempt is likely to havemasked variability in howheavily,
frequently and how long either NRT over-the-counter or
e-cigarettes were used by different smokers [12,52–54]. It
is also possible that there were differences between the
groups in their experience of unanticipated side effects. It
is precisely because of all these factors—type/brand of
NRT over-the-counter or e-cigarette, intensity and fre-
quency of usage and experience of unanticipated side
effects—that it is important to examine real-world effec-
tiveness. However, it also means that we cannot make
more exact statements about relative effectiveness of dif-
ferent products and ways in which they may be used.
Given thishugevariability itmaybemanyyearsbeforeone
couldaccumulateenoughreal-worlddata toaddress these
questions. Finally, the prevalence of e-cigarettes has been
increasing in England over the study period and this may
affect real-worldeffectiveness.Although theevidencedoes
not yet suggest an ‘early adopters’ effect—the current
results persisted after adjusting for the year of survey and
in a subgroup analysis limiting the data to a period when
e-cigarette usage had become prevalent—these findings
will need to be revisited to establish whether or not the
apparent advantage of e-cigarettes is sustained.
In conclusion, among smokers trying to stop without
any professional support, those who use e-cigarettes are
more likely to report abstinence than those who use a
licensed NRT product bought over-the-counter or no
aid to cessation. This difference persists after adjusting for
a range of smoker characteristics such as nicotine
dependence.
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